NICE backs GSK’s Zejula in advanced ovarian cancer
15th January 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women with newly diagnosed advanced ovarian cancer.
In the UK, around 7,500 women are diagnosed with ovarian cancer each year – 60% of which will be diagnosed at a late stage, where their cancer has spread and is potentially incurable.
The NICE recommendation covers Zejula use for the treatment of adult women with advanced, high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer who have completed and shown response to platinum-based chemotherapy.